BUZZ-GSK partner Adaptimmune jumps on good cell therapy data
** Adaptimmune up 30 percent on news that second solid tumour type responds to its cell therapy, boosting hopes for biotech company's NY-ESO SPEAR T-cells partnered with GlaxoSmithKline (Other OTC: GLAXF - news)
** Adaptimmune reports three partial responses (two confirmed and one to be confirmed) and one case of stable disease in the first four patients dosed in myxoid/round cell liposarcoma trial
** GSK licensed rights to NY-ESO cell therapy in September 2017 and UK drugmaker sees product as important part of its drive to rebuild oncology R&D. GSK shares up 0.6 percent
** Adaptimmune founded to exploit cell therapy technology originally developed at Oxford University and firm listed on Nasdaq (Frankfurt: 813516 - news) in 2015